Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Approves Labeling Change for VYVANSE(R) ADHD Treatment

By Pharmaceutical Processing | June 1, 2009

Shire plc hasannounced that the FDA has approved a changeto the prescribing information for its once-daily Attention DeficitHyperactivity Disorder (ADHD) treatment VYVANSE(R) (lisdexamfetaminedimesylate) CII, to include supplemental data that demonstrated significantADHD symptom control in children aged 6 to 12 from the first time pointmeasured (1.5 hours) through 13 hours postdose. VYVANSE is now the first andonly oral ADHD stimulant treatment to have 13-hour postdose efficacy data forpediatric patients included in its product labeling. “Children with ADHD who still exhibit symptoms into the evening might needa treatment that provides a long duration of effect from morning, throughhomework and family time,” said Michael Yasick, Senior Vice President of theADHD Business Unit at Shire. “The FDA approval of this labeling change forVYVANSE provides important additional information for physicians on theduration of effect of VYVANSE and use as a once daily treatment option.”This update to the VYVANSE product labeling is based on a 13-hour analogclassroom study that demonstrated improvements in behavior, inattention, andmath test scores in children aged 6 to 12 from the first time point measured(1.5 hours) through the last time point assessed (13 hours) postdose. Thisstudy supports the results of a previous Phase 2 laboratory school study inwhich VYVANSE demonstrated ADHD symptom control from the first time pointassessed (two hours postdose) with duration of efficacy up to 12 hourspostdose. The adverse events in the 12-hour study for patients taking VYVANSEduring the double-blind treatment period, which were greater than or equal to2 percent, were insomnia, decreased appetite, and anorexia.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE